Danish Novo Nordisk shares are rising steadily this year, zooming past British competitor GlaxoSmithKline.
Bloomberg recently reported that the company’s shares have gone up by 27 percent during 2014 with a total market cap of $120 billion, passing GSK by several billions which according to stock exchange experts comes as quite a surprise. Its 2014 sales forecast amounts to $15.8 billion, up from $14.8 billion last year.
According to the Bloomberg prognosis, Novo Nordisk’s head start is predicted to grow as the company’s sales increases in step with the major growth of the diabetes market in the years to come. Novo Nordisk is planning to hire 6000 new employees within research and production to its facility outside Copenhagen to meet the demand for the company’s products.